1. Rochu D, Chabri‘ere E, Masson P. Human paraoxonase: a promising approach for pre-treatment and therapy of organophosphorus poisoning. Toxicology 2007;233:47e59.
2. Costa LG, Cole TB, Furlong CE. Polymorphisms of paraoxonase (PON1) and their significance in clinical toxicology of organophosphates. J Toxicol Clin Toxicol 2003;41:37e45.
3. Aharoni A, Gaidukov L, Khersonsky O, et al. The ‘evolvability’ of promiscuous protein functions. Nat Genet 2005;37:73e6.
4. Khersonsky O, Tawfik DS. Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry 2005;44:6371e82.
5. Maxwell DM, Brecht KM, Chang F, et al. Toxicodynamic modelling of highly toxic organophosphorus compound. J Mol Neurosci 2006;30:129e31.
6. Leonid G, Dganit B, Shiri Y, et al. In vivo administration of BL-3050: highly stable engineered PON1-HDL complexes. BMC Clin pharmacol 2009;9:1e13.
7. Zhao M, Cui Y, Yuan L. Extraction and purification of rabbit serum paraoxonase. J China Medical University 2009;38:490e2.
8. Shigeaki I, Takeshi S, Hiroyasu M, et al. Rapid simultaneous determination for organophosphorus pesticides in human serum by LCeMS. J Pharm Biomed Anal 2007;44:258e64.
9. Wu S, Ye DQ. Implementation of ridit analysis in single unidirectional ordered data of multiple groups in SPSS. Chinese Health Statistics 2006;23:554.
10. Costa LG, McDonald BE, Murphy SD, et al. Serum paraoxonase and its influence on paraoxon and chlorpyrifos toxicity in rats. Toxicol Appl Pharmacol 1990;103:66e76.
11. Li WF, Costa LG, Furlong CE. Serum paraoxonase status: a major factor in determining resistance to organophosphates. J Toxicol Environ Health 1993;40:337e46.
12. Li WF, Furlong CE, Costa LG. Paraoxonase protects against chlorpyrifos toxicity in mice. Toxicol Lett 1995;76:219e26.
13. Xiong YQ, Zeng FD. Effect of neferine on toxicodynamics of dichlorvos for inhibiting rabbit cholinesterase. Acta Pharmacol Sin 2003;24:332e6.